Human medicines European public assessment report (EPAR): Epclusa, sofosbuvir / velpatasvir, Hepatitis C, Chronic, Date of authorisation: 06/07/2016, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Ribavirin Mylan (previously Ribavirin Three Rivers), ribavirin, Hepatitis C, Chronic, Date of authorisation: 10/06/2010, Revision: 10, Status: Authorised

Case Medical Research ◽

10.31525/cmr-1907582 ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis C ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report ◽

Three Rivers

Download Full-text

Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hairy Cell,Lymphoma, Follicular,Hepatitis B, Chronic,Hepatitis C, Chronic,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Melanoma,Multiple Myeloma, Date of authorisation: 09/03/2000, Revision: 31, Status: Authorised

Case Medical Research ◽

10.31525/cmr-39964f ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Hepatitis B ◽

Cell Lymphoma ◽

Interferon Alfa ◽

Hairy Cell ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Vosevi, sofosbuvir / velpatasvir / voxilaprevi, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-c4dbb9 ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis C ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Viekirax, ombitasvir / paritaprevir / ritonavir, Hepatitis C, Chronic, Date of authorisation: 14/01/2015, Revision: 17, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5ed974 ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis C ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): IntronA, interferon alfa-2b, Carcinoid Tumor,Leukemia, Hairy Cell,Lymphoma, Follicular,Hepatitis B, Chronic,Hepatitis C, Chronic,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Melanoma,Multiple Myeloma, Date of authorisation: 09/03/2000, Revision: 31, Status: Authorised

Case Medical Research ◽

10.31525/cmr-fcd076 ◽

2019 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Hepatitis B ◽

Cell Lymphoma ◽

Interferon Alfa ◽

Hairy Cell ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Viekirax, ombitasvir / paritaprevir / ritonavir, Hepatitis C, Chronic, Date of authorisation: 14/01/2015, Revision: 18, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5ee337 ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis C ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Rebetol, ribavirin, Hepatitis C, Chronic, Date of authorisation: 06/05/1999, Revision: 34, Status: Authorised

Case Medical Research ◽

10.31525/cmr-5ee330 ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis C ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Vosevi, sofosbuvir / velpatasvir / voxilaprevi, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 4, Status: Authorised

Case Medical Research ◽

10.31525/cmr-c3f2a5 ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis C ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Sovaldi, sofosbuvir, Hepatitis C, Chronic, Date of authorisation: 16/01/2014, Revision: 18, Status: Authorised

Case Medical Research ◽

10.31525/cmr-babd5b ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis C ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text

Human medicines European public assessment report (EPAR): Exviera, dasabuvir, Hepatitis C, Chronic, Date of authorisation: 14/01/2015, Revision: 15, Status: Authorised

Case Medical Research ◽

10.31525/cmr-6036cc ◽

2019 ◽

Author(s):

Keyword(s):

Hepatitis C ◽

Assessment Report ◽

European Public ◽

European Public Assessment Report

Download Full-text